Intuitive Surgical EVP sells $183,260 in company stock

Intuitive Surgical's Executive Vice President and Chief Legal and Compliance Officer, Gary Loeb, disposed of 400 shares of the company's common stock on November 10, 2026. The sale occurred at a price of $458.15 per share, amounting to $183,260. This transaction was executed pursuant to a pre-planned trading strategy, as mandated by Rule 10b5-1 of the Securities and Exchange Commission, and will expire on January 29, 2027. After the sale, Loeb holds 6,236 shares of Intuitive Surgical common stock.

The stock price of Intuitive Surgical is currently trading at $443.59, indicating a premium compared to the sale price. Despite this, the shares have experienced a 21.68% decline year-to-date. Intuitive Surgical is a significant player within the healthcare equipment industry, boasting a market capitalization of $152.49 billion.

InvestingPro analysis suggests that the stock is currently undervalued, trading below the company's estimated Fair Value. Investors can access a wealth of detailed analysis and exclusive ProTips for Intuitive Surgical, as well as insights on 1,400+ other US equities, through the InvestingPro platform.

In recent news, Intuitive Surgical reported a substantial third-quarter revenue of $3.05 billion, exceeding both Oppenheimer's estimate of $2.92 billion and the consensus of $2.91 billion. However, GAAP earnings per share were reported at $1.49, falling short of Oppenheimer's estimate of $2.38 and the consensus of $2.39. This discrepancy can be attributed to a $450 million litigation settlement, which contributed to an overall shortfall of $140 million and $0.35 per share.

Despite this, Intuitive Surgical's performance across its Systems, Services, and Instruments & Accessories segments remained robust. Systems revenue alone reached $769 million, surpassing the Street estimate of $679 million. Nonetheless, some analysts have lowered their price targets for the company. RBC Capital reduced its price target to $550 from $575, citing potential U.S. volume headwinds as procedure growth slows.

Mizuho also lowered its price target to $400 from $415, maintaining a Neutral rating. On a more positive note, Truist Securities reaffirmed its Buy rating with a $510 target, highlighting a significant increase of 40% in net da Vinci placements in the third quarter. Stifel also maintained its Buy rating with a $550 target, emphasizing the company's strong third-quarter performance.

Finally, Oppenheimer reiterated its Outperform rating with a $500 target following the earnings report.